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INTRODUCTION
It is now clear that in addition to faster platelet and neu-
trophil recoveries, there is a survival advantage for high-risk
patients receiving granulocyte colony-stimulating factor
(G-CSF)-mobilized peripheral blood mononuclear cells
(GPBMC) in place of bone marrow (BM) as a source of
HLA-identical stem cells from related donors [1]. The bio-
logical basis for the survival advantage, the different pace of
hematological recovery, and varying rates of acute and
chronic graft-versus-host disease (GVHD) is still unclear.
One theory credits differences in the numbers and functions
of accessory cell populations like CD14 or CD4 cells [2-4].
An alternative hypothesis involves qualitative as well as
quantitative differences in CD34 cells, which have been
shown [5-8] to differ in surface phenotype, metabolic activ-
ity, and cycling status.
Identifying the GPBMC components responsible for
the favorable differences in transplantation outcome is criti-
cal for optimizing the hematopoietic graft. A first step in
this direction is to determine how the various cell popula-
tions in GPBMC differ from their BM counterpart. Toward
this end, we began by comparing the gene expression pat-
tern of CD34 cells from GPBMC and BM by high-density
nucleotide array analysis for over 6400 well-characterized
human transcripts and expressed sequence tags.
The data indicate that the array analysis is sufficiently
reproducible to identify consistent differences between mar-
row- and blood-derived sources of CD34 cells. The speciﬁc
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ABSTRACT
A prospective randomized trial has shown that there is a survival advantage for allogeneic transplant recipients who
received granulocyte colony-stimulating factor (G-CSF)-stimulated peripheral blood mononuclear cells (GPBMC)
versus those who received bone marrow (BM) as a source of stem cells. The biological basis for this advantage is
not clear and may be attributable to qualitative as well as quantitative differences in the CD34 cells, T cells, and/or
the monocytes transplanted. To begin to address this issue, gene expression patterns in CD34 cells isolated from
these 2 stem cell sources were compared to identify functional pathways that may distinguish these 2 populations.
CD34 cells were isolated to purity from the BM and peripheral blood stem cells of multiple healthy donors. (The
complete data set will be available at http://parma.fhcrc.org/lgraf upon publication.) Two separate RNA prepara-
tions from pooled samples from both sources were analyzed by Affymetrix Oligonucleotide Array chips for expres-
sion of over 6400 human genes. Comparative analyses among the samples showed that a small set of 28 sequences
increased and 38 sequences decreased in expression more than 3-fold in both of the GPBMC samples compared to
those in BM samples. More highly expressed genes include several for nuclear proteins and transcriptional factors.
Functional categorization of the genes decreased in expression indicated sequences influential in cell cycle pro-
gression, in agreement with the recognized quiescence of circulating CD34 cells. Multiple transcriptional regula-
tors and chemokines were also found to be decreased. These data emphasize that in addition to increased numbers
of CD34 cells, G-CSF mobilization also results in significant qualitative changes. Whether they impact engraft-
ment remains to be determined.
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differences in gene expression observed conﬁrm known bio-
logical differences between these stem cell sources and sug-
gest functions that theoretically may confer an engraftment
advantage on GPBMC CD34 cells.
MATERIALS AND METHODS
Cell Isolation and Processing
Peripheral blood stem cell donors were treated by sub-
cutaneous injection with recombinant human G-CSF
(Amgen Inc, Thousand Oaks, CA) at a dose of 16 µg/kg for
5 days. Leukapheresis was performed using a Cobe Spectra
continuous flow blood cell separator (Cobe Laboratories,
Lakewood, CO) on 2 consecutive days beginning on day 4
of G-CSF administration. Aliquots of the GPBMC prod-
uct were collected after written informed consent using
forms approved by the Institutional Review Board of the
Fred Hutchinson Cancer Research Center (FHCRC) for
collection of samples for research purposes. Cells were
washed twice in Hanks’ balanced salt solution (Gibco-
BRL, Rockville, MD), and erythrocytes were removed by
hypotonic lysis. Cells that could not be processed immedi-
ately were cryopreserved. Magnetic bead enrichment of
CD34 cells was accomplished with a CD34 isolation kit
(Miltenyi Biotec, Auburn, CA) and the sensitive mode of
positive selection on an AutoMacs magnetic separation
apparatus (Miltenyi Biotec).
CD34-enriched cells from BM were obtained through
the Cell Processing Shared Resource of the FHCRC. We
chose to use cadaveric marrow as the main source of BM
CD34 cells to obtain adequate RNA for analysis. Although
we cannot exclude the possibility that the longer processing
and variable time of cold ischemia may affect gene expres-
sion in these cells, studies in our laboratory [9] have shown
that the CD34 cells in this marrow are functionally equiva-
lent to those in iliac crest marrow regarding colony plating
efficiency and cytokine responsiveness. Other laboratories
[10-12] have shown cadaveric marrow to be comparable to
iliac crest marrow in the level of CD34 cells, number and
quality of clonal hematopoietic progenitors, and long-term
multilineage hematopoietic engraftment. BM cells were har-
vested from donor vertebral bodies at the Puget Sound
Blood Center (Seattle, WA) and processed for CD34 selec-
tion with a Baxter Isolex 300 SA system according to manu-
facturer’s instructions. Cells were cryopreserved until use.
CD34 cells from both sources were isolated to >95%
purity by monoclonal antibody staining and ﬂow cytometry
(fluorescence-activated cell sorting [FACS]). Briefly, pre-
enriched cells were labeled with HPCA-2-phycoerythrin
(Becton Dickinson Immunocytometry Systems, San Jose,
CA) and selected on a Becton Dickinson Vantage II with
gates for exclusion of nonviable cells (propidium iodide pos-
itive) and cells with high side scatter. All antibodies were
from Becton Dickinson.
RNA Isolation and Complementary DNA Synthesis
All RNA isolation and puriﬁcation for oligonucleotide
array analysis and polymerase chain reaction (PCR) quan-
titation was accomplished with the RNeasy Mini Kit (Qia-
gen, Valencia, CA) reagents. Briefly, cells were pelleted
immediately after isolation, lysed in the guanidium isothio-
cyanate–containing denaturing buffer, and passed through a
QiaShredder (Qiagen) to break up clumps and to fragment
genomic DNA. Samples were stored in this buffer at –80°C
until adequate numbers of cells (10 × 106) had been col-
lected. RNA from pooled lysates was adsorbed to RNeasy
columns, washed, and eluted in water. Traces of contami-
nating genomic DNA were removed by digestion with RQ1
Rnase-free DNase (Promega, Madison, WI) for 15 minutes
at 37°C according to manufacturer’s directions. RNA was
again puriﬁed on RNeasy columns. Quantity and quality of
the RNA was assessed by spectrophotometric analysis at
260 nm and 280 nm. Five percent of each sample was dena-
tured by heating for 5 minutes at 65°C, electrophoresed on
a 1% agarose gel, stained with ethidium bromide, and
checked for quality.
Complementary DNA (cDNA) for array analysis was
synthesized from 8 µg to 16 µg total RNA. First- and second-
strand cDNA synthesis was carried out with the SuperScript
Choice (Gibco) reagents according to the manufacturer’s
protocol, except that ﬁrst-strand synthesis was carried out at
42°C with an oligo-dT primer containing the T7 RNA
polymerase binding site [5′-GCCAGTGAATTGTAATAC
GACTCACTATAGGGAGGCGG-(dT)24-3′] (Genset, La
Jolla, CA). Blunted, double-stranded cDNA was then puri-
ﬁed by phenol-chloroform extraction and ethanol precipita-
tion. Template cDNA for PCR quantitation was synthesized
as above from DNase-treated total RNA with an oligo
(dT)12-18 primer (Pharmacia, Piscataway, NJ).
Synthesis of Biotin-Labeled cRNA
Biotin-labeled cRNA for probing on the Affymetrix
arrays was synthesized by in vitro transcription (IVT) of the
double-stranded cDNA with the Enzo BioArray High Yield
Transcript Labeling Kit (Enzo Diagnostics, Farmingdale,
NY). Brieﬂy, 8 µg-16 µg cDNA was incubated for 4 hours in
the presence of T7 RNA polymerase and ribonucleotides,
which included bio-11-UTP and bio-11-CTP. Newly synthe-
sized cRNA was puriﬁed with an RNeasy column to remove
unincorporated ribonucleotides, as described above, and pre-
cipitated by addition of 0.5 volumes 7.5M ammonium acetate
and 2.5 volumes cold absolute ethanol. Biotinylated cRNA was
resuspended in H2O and quantiﬁed by spectrophotometry. A
minimum of 20 µg target cRNA was fragmented in fragmen-
tation buffer (200 mmol/L Tris-acetate, pH 8.1, 500 mmol/L
potassium acetate, 150 mmol/L magnesium acetate) by heat-
ing to 94°C for 35 minutes to improve hybridization kinetics.
Samples were frozen at –20°C until hybridization to arrays
could be performed.
Hybridization, Washing, Staining, and Scanning of
Affymetrix Probe Arrays
All procedures were performed according to standard
Affymetrix (Santa Clara, CA) protocols (P/N 700222 rev. 4)
for HuGeneFL 6800 Arrays. Target biotinylated cRNA was
hybridized overnight at 45°C in a mix that included 10 µg
fragmented RNA, 6× SSPE, 0.005% Triton-X 100, and
100 µg/mL herring sperm DNA. Chips were washed and
stained with phycoerythrin-streptavidin. The signal was
ampliﬁed by addition of biotinylated goat anti-streptavidin
antibody. After washing, chips were scanned on a scanner
from Axon Instruments, Inc (Union City, CA).
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Data Analysis
Expression analysis was conducted with the standard
Affymetrix analysis software algorithms (Affymetrix Microar-
ray Suite 4.0). Determination of which genes were detectable
or nondetectable (absolute analysis) was based on a number of
parameters, primarily the number of probe pairs interrogat-
ing each gene in which the intensity of the perfect-match
hybridization signal exceeded that of the mismatch hybridiza-
tion signal [13]. All absolute analysis data were scaled by over-
all intensity to an arbitrary value of 1000 to allow comparison
of samples. For differential expression analysis, 1 sample was
declared as the baseline, and increases or decreases in expres-
sion relative to this sample were calculated.
Semiquantitative PCR
Expression level of RNA transcripts was confirmed by
semiquantitative reverse transcriptase PCR (RT-PCR) with
sequence-specific oligonucleotide primers. Total RNA was
puriﬁed and DNase-treated as described for the DNA array
analysis, then reverse transcribed into cDNA with an oligo
(dT)12-18 primer. The cDNA was diluted and used at a tem-
plate concentration and cycle number that was determined to
be within the logarithmic amplification range for each
sequence, as described previously [14]. Ampliﬁcation prod-
ucts were separated on a 3% agarose gel and quantiﬁed by
ethidium bromide staining with the Stratagene EagleEye
Imaging system (La Jolla, CA). PCR conditions were 30 sec-
onds at 94°C, 45 seconds at 56°C, and 30 seconds at 72°C,
with 30 cycles for interleukin-8 (IL-8), myeloperoxidase, and
β2microglobulin (β2m); 31 cycles for CD83, ITBA4, and
cyclin A; and 26 cycles for glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH). A10 and N-myc were ampliﬁed from
5000 cell equivalents for 33 cycles with the same parameters
as above except for a 60°C annealing temperature.
RESULTS
Cell Source and Sample Characterization
Gene expression was analyzed for 4 different pools of
CD34 cells, 2 from BM and 2 from GPBMC. Cells were
pooled from multiple donors, as seen in Table 1, to equalize
for individual differences between donors and to obtain
adequate quantities of RNA for the analysis. The majority
of the BM cells were from normal cadaveric donors,
whereas the GPBMC-derived cells were from living,
healthy peripheral blood stem cell donors. All CD34 cells
were first enriched by magnetic bead selection, then iso-
lated to >95% purity by flow cytometry, as described in
Materials and Methods. Both the BM and GPBMC pools
consisted of a mixture of 80% cryopreserved and 20%
freshly isolated cells. Cryopreserved samples were thawed
quickly at 37°C, washed once, and processed immediately
for enrichment and/or FACS. Selected cells were lysed
immediately for RNA isolation. Total RNA purified from
the cell pools was converted to double-stranded cDNA,
which in turn was used as a template for synthesis of the
biotinylated cRNA target. The target cRNA was probed
ﬁrst with an Affymetrix test chip, which assesses hybridiza-
tion intensity and extent of hybridization to oligonu-
cleotides representing the 3′ and 5′ ends of 2 housekeeping
genes, actin and GAPDH. Table 1 summarizes the charac-
teristics of the sample pools as well as the quantity of RNA
and the quality of the ﬁnal biotinylated cRNA synthesized
independently from each source. By these criteria, all
cRNA preparations were of similar quality and could be
probed on the HuGeneFL chip.
Comparison of Global Expression Differences
Between Samples
Given that we were comparing 2 pools of relatively het-
erogeneous cell populations, the analysis was designed to
measure the consistency of the array data and known sources
of signal heterogeneity [15,16], as well as the differences
between the 2 sources of cells. For this purpose, the samples
were scaled to an arbitrary value of 1000 to normalize for
differences in overall intensity. RNA transcripts correspond-
ing to between 2941 and 3362 sequences, representing
41.3% to 47.2% of all sequences encoded on the chip, were
present in the different pools at a hybridization intensity and
speciﬁcity signiﬁcantly over background and noise levels. A
preliminary analysis of the mRNA levels of all of these
sequences provided a test of the relative variability within
and between the 2 comparison groups. This analysis is repre-
sented in Figure 1. The technical variability produced by the
in vitro cDNA synthesis and target cRNA preparation was
assessed by carrying out 2 separate target syntheses from the
ﬁrst BM CD34 pool (BM-1). As shown in Figure 1A, very
few differences were introduced by this procedure. Addi-
tional heterogeneity in signal was observed between the
2 GPBMC pools (Figure 1B). Nevertheless, the greatest
Table 1. Characterization of CD34 Target Populations and RNA Quality*
3′-5′ Ratio†
CD34 Source No. of Donors No. of Cells, × 106 Total RNA, µg Actin GAPDH
BM-1a‡ 6 13.5 16.8 1.0 1.1
BM-1b‡ 1.1 1.2
BM-2 5 9.7 12.3 1.2 1.5
GPBMC-1 23 12.3 12.6 1.0 1.2
GPBMC-2 20 10.4 22.8 1.1 1.6
*GAPDH indicates glyceraldehyde-3-phosphate dehydrogenase; BM, bone marrow; GPBMC, granulocyte colony-stimulating factor–mobilized
peripheral blood mononuclear cells.
†A ratio of <1.5 for at least 1 of these housekeeping genes is indicative of high-quality RNA and full-length complementary DNA (cDNA) synthesis.
‡A second cDNA and cRNA synthesis from the same total BM-1 RNA sample was prepared to assess variability introduced during synthesis.
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differences were detected when comparing either of the
GPBMC samples with the BM samples (Figures 1C and 1D).
A comparative analysis of gene expression between
GPBMC and BM was done by declaring 1 sample, BM-1b,
as the baseline for comparison. The differences in expres-
sion level, as well as a fold-difference value, were then calcu-
lated for all individual sequences in all other samples. Based
on these results, we chose an arbitrary threshold of a 3-fold
difference to identify genes to be considered differentially
expressed. Twenty-eight transcript probes showed greater
hybridization intensity in both GPBMC pools compared to
the baseline BM pool, and 38 were signiﬁcantly decreased.
By the same criteria, only 2 sequences were increased and
none were decreased upon comparison of BM-1a and BM-2
to the baseline BM-1b. A comparison of GPBMC-1 and
GPBMC-2 could be done only by declaring one of them
(GPBMC-2) as the baseline. By this method, 39 sequences
were increased and 33 decreased between these samples.
None overlapped with the previous sets.
Characteristics of the Set of Differentially Expressed
Genes
The 28 sequences with >3-fold increase in expression
and the 38 sequences with >3-fold decrease in expression
are listed in Tables 2 and 3, together with annotation of
their probable function and the calculated fold difference
in expression level. Two of the sequences were represented
by 2 sets of oligonucleotide probes on the chip, both of
which gave similar results. Names and functional descrip-
tions are derived from information available in public data-
bases, primarily the National Center for Biotechnology
Information (NCBI) UniGene/GenBank [17] and the
Weizmann Institute GeneCard [18] databases. The
sequences increased in expression in GPBMC are not eas-
ily categorized. There are a number of nuclear proteins,
such as histones and LXRα, and transcriptional regulatory
molecules like PHOX1, N-myc, and zinc finger proteins.
IRF2, an important interferon regulatory factor, is upregu-
lated, as are genes such as MX1 and GBP2, known to be
induced by interferons.
The majority of the sequences lower in expression in
GPBMC fall into 2 functional categories: S-phase– or G2-
M transition cell cycle–related transcripts and myeloid cell
program targets of the C/EBP (CCAAT/enhancer binding
protein) transcription factor family. The sequences are
ordered by presumed functional relationship. The mean
of the fold difference value calculated by standard
Affymetrix algorithms for all comparisons are shown on
the right. The complete data set will be available at
http://parma.fhcrc.org/lgraf upon publication.
Confirmation of Differential Expression of Transcripts
To verify differences in RNA level by an independent
method, we chose 7 sequences from the set of differentially
Figure 1. Global survey of differences in messenger RNA levels between samples. The plots show variation in ﬂuorescent signal intensities (Aver-
age Difference Intensities), which reﬂect the expression level of all of the sequences judged in an absolute analysis to be present in all of the samples.
Dotted lines indicate 3- and 5-fold differences in signal intensity. A, The variability produced by 2 separate biotinylated target complementary
RNA preparations of the ﬁrst marrow pool. B, Heterogeneity in signal found in a comparison between 2 different pools of granulocyte colony-
stimulating factor–mobilized peripheral blood mononuclear cells (GPBMC). C and D, Differences found in the comparisons of the GPBMC and
bone marrow (BM) samples.
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expressed genes and assessed their transcription level by RT-
PCR. Two were genes found to be increased, and 5 were from
those found to be decreased in the microarray analysis. Three
new pools of cells from BM and GPBMC were isolated for
the analysis. Sequences of oligonucleotide primers are listed
in Table 4. The decreased genes were chosen to represent the
myeloid/inflammation program, cell cycle–related, and
immune function categories noted from the annotation. The
2 housekeeping genes, β2m and GAPDH, which showed no
change in transcription level in any of the samples, were also
tested. The results from a semiquantitative PCR conﬁrming
the increases and decreases found in the microarray data for
all 9 sequences are shown in Figure 2. The degree of change
in expression for the individual genes differed between the
2 methods. The fold-difference values calculated for array
data can be affected by noise or very low expression in either
the baseline or experimental sample.
DISCUSSION
We used DNA microarray technology to assess the
expression level of over 6400 cellular genes in CD34 cells
from the 2 major sources of hematopoietic cells used for
transplantation, BM and GPBMC. A specific question in
this study was whether, given certain technical limitations, a
global analysis of gene expression can yield relevant infor-
mation for such heterogeneous populations as CD34 cells.
Recent expression profiling studies of human CD34 cells
[19,20] or their murine equivalents [21,22] have focused on
identiﬁcation of genes selectively expressed during differen-
tiation of hematopoietic stem cells or novel sequences spe-
cific to these populations. Limitations include (1) the
amount of mRNA necessary for such an analysis, which pro-
hibits collection of a large enough number of samples to
detect small, but possibly signiﬁcant, expression differences,
and (2) the cost of commercial microarrays, which limits the
number of analyses.
We analyzed 2 possible sources of variability in the tar-
get cRNA preparations that could obscure true biological
differences: the in vitro cDNA and cRNA synthesis steps
and the donor pool heterogeneity. The former was found to
contribute little to variation. Some sample heterogeneity,
however, was seen in the comparison of one GPBMC sam-
ple with another, and the need to analyze at least 2 samples
to control for this source of heterogeneity was obvious.
Identifying sequences that are signiﬁcantly different in
expression between any 2 (or more) cell populations or
treatment groups is not simple. We chose stringent criteria
and, in doing so, have probably underestimated the number
of genes that vary in transcription between the 2 cell
sources. We expect that more sophisticated analysis software
algorithms and, more importantly, additional samples will
Table 2. Transcripts Increased in Expression >3-Fold in CD34 GPBMC*
Identifier Cluster ID Name Annotation Fold Difference
M95929 Hs.155606 PHOX1 Homeobox protein 17.8
D78014 Hs.74566 DPYSL3 Dihydropyrimidinase-like 3 17.7
M55543 Hs.171862 GBP2 Guanylate binding protein 2, INF inducible 15.7
M38591 Hs.119301 S100A10 Calcium-binding protein; annexin II ligand 13.9
D16583 Hs.1481 HDC Histidine decarboxylase 13.2
D38583 HS.256290 S100A11 Calcium-binding protein A11, calgizarrin 8.6
M13241 Hs.25960 NMYC N-myc 7.7
X12876 Hs.65114 KRT18 Keratin 18 6.3
X82209 Hs.268515 MN1 Meningioma 1 6.2
U09770 Hs.17409 hCRHP LIM domain, Zn-finger, cellular repair 5.8
D90224 Hs.181097 TNFSF4 TNF superfamily, member 4 (gp34) 5.8
D50683 Hs.82028 TGFBR2 TGF-β II Receptor α 5.5
U00952 Hs.8068 HPIP Hematopoietic PBX-interacting protein 5.2
X57985 Hs.2178 H2BFQ H2A histone family, member Q 4.9
M33882 Hs.76391 MX1 MX1 (INF-inducible protein p78) 4.8
U22662 Hs.81336 NR1H3 Nuclear receptor LXR-α 4.7
HG4126 none ZPF4 Zn-finger protein 234 4.3
Z84721 Hs.272003 HBZ Zeta-globin 1 4.2
U28749 Hs.2726 HMGIC High-mobility group protein I-C 4.1
U90551 Hs.28777 H2AFL Histone 2A-like protein 4.1
M80899 Hs.301417 AHNAK AHNAK nucleoprotein (desmoyokin) 4.0
D84110 Hs.80248 RBP-MS RBP-MS/type 4; RNA binding protein 3.9
X15949 Hs.83795 IRF2 Interferon regulatory factor 2 3.8
D38522 Hs.74454 KIAA0080 Synaptotagmin-4 homologue 3.7
D00017 Hs.217493 ANXA2 Annexin II 3.6
M59499 Hs.233950 TFPI Serine protease inhibitor 3.5
U79271 Hs.300642 SDCCAG8 Colon cancer antigen 8 3.4
L13278 Hs.83114 CRYZ Crystallin (quinone reductase) 3.4
* Identiﬁer, names, and functional descriptions are derived from information available in public databases, primarily the National Center for
Biotechnology Information (NCBI) UniGene database, GenBank, and the Weizman Institute GeneCard system. GPBMC indicates granulocyte
colony-stimulating factor–mobilized peripheral blood mononuclear cells; INF, interferon;  TNF, tumor necrosis factor; TGF, tumor growth factor.
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Table 3. Transcripts With >3-Fold Decrease in Expression in Both Comparisons*
Identifier Cluster ID Name Annotation Fold Difference
M83667 Hs.76722 NF-IL6-β C/EBP delta –24.3
X13293 Hs.179718 B-myb gene May work with C/EBP –8.6
J04990 Hs.100764 Cathepsin G gene Granule protein (C/EBP controlled?) –5.8
M19507 Hs.1817 Myeloperoxidase Major granule protein, C/EBP controlled –5.0
X55668 Hs.928 Proteinase 3 Major granule protein, C/EBP controlled –24.9
M20203 Hs.99863 Neutrophil elastase Major granule protein, C/EBP controlled –64.5
X55989 Hs.166037 ECRP Eosinophil cationic-related protein –7.4
M96326 Hs.72885 AZU1 Azurocidin 1; serine protease –3.3
M57731 Hs.75765 Gro-β Chemokine; C/EBP control –4.8
M23178 Hs.73817 MIP I Chemokine; C/EBP control –10.3
M28130 Hs.624 interleukin 8; MDNCF Chemokine; C/EBP control –6.1
X51688 Hs.85137 Cyclin A Controls G1-second and G2-M transition –5.2
M74093 Hs.9700 Cyclin E1 G1-second transition –4.1
X54941 Hs.77550 Cks1; cdc28 Binds to catalytic subunit of cyclins –4.0
U73379 Hs.93002 Cyclin-selective ubiquitin Cyclin-specific degradation –3.7
X65550 Hs.80976 MKI67 Ki-67 cell proliferation antigen –5.5
X55990 Hs.73839 RNASE3 Ribonuclease family, 3 –5.7
X67155 Hs.270845 MKLP1 Mitotic kinesin-like protein –5.6
U37426 Hs.8878 KNSL1 Kinesin-like 1 –6.7
X59618 Hs.75319 RR2 ribonucleotide reductase DNA replication and cell proliferation –6.1
L11329 Hs.1183 PAC-1 Regulates mitogenic signal transduction –21.6
U09579 Hs.179665 CDKN1A CDK 1A (p21, Cip1) –9.2
U14518 Hs.1594 CENPA Centromere protein A (17kD) –4.4
V00594 Hs.118786 Metallothionein Regulated by metals or glucocorticoids –133.2
J03910 Hs.173451 MT1G Metallothionein-IG –7.6
X51757 Hs.3286 Heat-shock protein HSP70B′ “Heat shock” –129.8
D85429 Hs.82646 Heat-shock protein 40 “Heat shock” –15.4
D86956 Hs.36927 KIAA0201 gene “Heat shock” –8.0
D14695 Hs.146393 KIAA0025 Stress response, DNA repair –5.5
M30703 Hs.270883 Amphiregulin EGF type GF –17.6
D88422 Hs.2621 Cystatin A Cysteine protease inhibitor –9.2
U74612 Hs.239 Fork head homolog 11A Glucose metabolism response –12.9
L49054 Hs.85195 MLF1 Myeloid leukemia gene 1 –5.9
Z11697 Hs.79197 HB15 CD83; B cell activation –4.9
Y07707 Hs.119018 ITBA4 NRF, NF κB repressor –6.9
J05459 Hs.2006 Glutathione transferase M3 Protein modification –4.9
M31166 Hs.2050 TSG-14 Tumor necrosis factor–inducible –4.6
M59465 Hs.211600 TNF-α inducible protein A20 Anti-apoptotic? –8.7
*Identiﬁers, names, and functional descriptions are derived as in Table 2. C/EBP indicates CCAAT/enhancer binding protein.
Table 4. Oligonucleotide Primers for PCR Quantitation*
Transcript Sense Primer Antisense Primer
β2M ATGTCTCGCTCCGTGGCCTTAGCT ATGTCTCGCTCCGTGGCCTTAGCT
GAPDH AAAGGGTCATCATCTCTGCC TGACAAAGTGGTCGTTGAGG
IL-8 TACTCCAAACCTTTCCACCC AACTTCTCCACAACCCTCTG
MPO ATCTGCGACAACACAGGCATCACC AGTCTAGTTCCTGAGCTGTGCTCC
A10 TTACATTTCACAAATTCGCTGGG AACTCTTATCAGGGAGGAGCGAAC
NMYC GTAATGAGAGGTGGCTTTTGCG TTTGCATTTACCCAGTTCTATGCAC
CYCLA CTGGCCTGAATCATTAATACGA GCCAAATATCTAAGACAGATAC
CDC8 GACATGAGCAGAGCGATGGAG TCAGAGGTATGTTTCTGTGTCAATCG
ITBA4 GTAAATCTGGTGAGGGCATACGG CTTGAGGCATAACAAGCTCGTAATG
CD83 CTGTACCAGCCCAGATGTTTTACG AGGATAATGACTCAATGGAGTTTCGA
*All sequences are written 5′ to 3′. PCR indicates polymerase chain reaction; β2m, β2microglobulin; GAPDH, glyceraldehyde-3-phosphate dehy-
drogenase; IL, interleukin.
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add power to the analysis and allow us to identify genes with
smaller but consistent differences in expression level.
Several studies [5-8] have addressed speciﬁc alterations in
CD34 cells from GPBMC compared to those from BM.
These alterations include surface phenotype, metabolic activ-
ity, cycling status, and tolerizing potential. Few, if any,
GPBMC CD34 cells are in S phase, in contrast to 30% to
60% of BM CD34 cells. The markedly low expression of clas-
sic markers of S phase and G2-M transition, such as cyclin A,
cyclin E1, RR2 ribonucleotide reductase, and Ki-67, detected
in the array analysis are in agreement with this quiescent phe-
notype. Low levels of factors such as PAC-1, cyclin-selective
carrier protein, cdc28, and kinesins may also be associated
with the noncycling status of the GPBMC CD34 cells.
Figure 2. Reverse transcriptase–polymerase chain reaction (RT-PCR) expression analysis of sequences found to be differentially expressed by high-
density oligonucleotide array. Three samples each of CD34 cells were isolated from granulocyte colony-stimulating factor–mobilized peripheral
blood mononuclear cells (GPBMC) and bone marrow (BM); the cells were lysed; and RNA was isolated and reverse transcribed into complementary
DNA (cDNA) with an oligo-(dT)12-18 primer. Template consisted of cDNA from the equivalent of 2000 cells. All samples were ampliﬁed in dupli-
cate with the appropriate primers as described in Materials and Methods. Ampliﬁcation products were separated on a 3% agarose gel and stained
with ethidium bromide (top). The relative intensity of each band was quantitated with the Stratagene EagleEye imaging system. A graphical repre-
sentation of the mean of each pair of duplicate bands is shown in the bottom panel. IL indicates interleukin; MPO, myeloperoxidase; GAPDH, glyc-
eraldehyde-3-phosphate dehydrogenase; β2m, β2 microglobulin.
DNA Array Analysis of CD34 Cells
493B B & M T
Experimental models [23] have shown a correlation
between stem cell engraftment and cell cycle phenotype
after cytokine stimulation, with quiescence providing a com-
petitive advantage. Cycling versus noncycling cells, and
mobilized cells in general, also display differences in adhe-
sion molecule expression or conformation [24,25], but we
observed no differences at the transcript level for these mol-
ecules. Other expected characteristics of G-mobilized prod-
ucts, such as lower CD38 and CD71 expression and higher
expression of MDR1, the primary pump responsible for
rhodamine 123 efflux, were noted but did not exceed the
“3-fold in both comparisons” cutoff.
Of particular interest were the decreased levels of
C/EBP β and the set of myeloid-speciﬁc genes and proin-
flammatory cytokines known to be under the control of
C/EBP transcription factors and B-myb [26,27]. G-CSF has
proven itself to be a potent anti-inﬂammatory immunomod-
ulator [7] by inhibiting the production or activity of IL-1,
tumor necrosis factor α, and interferon γ. Much of this
effect, as well as the mobilization by G-CSF of progenitors
and other cells, is mediated via neutrophils [28,29]. These
factors may explain the decrease in expression of many
chemokines, such as IL-8, GRO3, and macrophage inﬂam-
matory protein 1α, as well as myeloperoxidase, elastase, and
proteinase 3. Many of the transcripts in the list of down-
regulated genes have not been investigated in relation to
CD34 cells. Those such as CD83 [30], which has been pos-
tulated to play a role in activation or inhibition of immune
response, are, however, of particular interest given the
hypothesis that CD34 cells may serve as “nonprofessional
antigen-presenting cells.”
Which, if any, of these differences between marrow-
and blood-derived CD34 cells actually confers a functional
advantage in vivo is speculative. Clearly, all the major com-
ponents of GPBMC, including T cells and monocytes,
need to be evaluated to identify the most relevant qualita-
tive differences between these 2 transplantation products.
Previous studies [2-4] already suggest that these accessory
populations in GPBMC differ in both number and gene
expression from those in marrow or nonmobilized blood.
A more complete analysis of these differences, together
with an association of these differences with function, will
help to instruct the future development of optimal cell-
based therapies.
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